News
ITRM
0.1819
+1.73%
0.0031
Weekly Report: what happened at ITRM last week (0302-0306)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 6d ago
Iterum Therapeutics cut to Hold at Maxim after delisting notice
TipRanks · 6d ago
Iterum Therapeutics downgraded to Hold from Buy at Maxim
TipRanks · 6d ago
Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives
TipRanks · 6d ago
Iterum Therapeutics Requests Nasdaq Hearing to Halt Delisting Suspension
Reuters · 03/03 22:05
Morning News Wrap-Up 3/3/26: Tuesday’s Biggest Stock Market Stories!
TipRanks · 03/03 17:37
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 03/03 17:05
Dow Dips 900 Points; Best Buy Posts Upbeat Earnings
Benzinga · 03/03 14:56
Why Is Iterum Therapeutics Stock (ITRM) Down Today?
TipRanks · 03/03 14:21
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 03/03 12:05
Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Benzinga · 03/03 10:27
Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options
TipRanks · 03/02 23:12
Nasdaq orders Iterum Therapeutics delisting for sub-$1 bid price
Reuters · 03/02 22:01
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 03/02 21:06
Weekly Report: what happened at ITRM last week (0223-0227)?
Weekly Report · 03/02 09:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 02/24 21:05
Weekly Report: what happened at ITRM last week (0216-0220)?
Weekly Report · 02/23 09:30
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 02/20 21:05
Iterum Therapeutics Shareholders Reject Key Capital Proposals
TipRanks · 02/18 23:00
More
Webull provides a variety of real-time ITRM stock news. You can receive the latest news about Iterum Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ITRM
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.